Blood coagulation protein

Blood coagulation proteins (also known as clotting factors) are a family of plasma proteins essential for the hemostatic process that controls bleeding and wound healing. They function as enzymes—primarily serine proteases—that are sequentially activated in the coagulation cascade after blood vessel injury, leading to conversion of fibrinogen to fibrin and formation of a stable clot[1][4][7][10]. Important members include fibrinogen (Factor I), prothrombin (Factor II), and various others such as factors VIII, IX, X, XI, and XIII, each with specific roles in the cascade[6][10]. Their deficiency, dysfunction, or overactivity leads to disorders such as hemophilia or pathological thrombosis[5][7][8]. Many are important therapeutic targets—either for inhibition to prevent thrombosis (e.g., with direct oral anticoagulants or warfarin), or for replacement in bleeding disorders (e.g., hemophilia therapy)[5][6][7][9][10]. **Note:** This entry is considered partially incorrect: “Blood coagulation proteins” is not a specific molecule or receptor but a collective term for multiple enzymatic proteins (mainly serine proteases) involved in the coagulation cascade, each with unique biology, disease roles, and drug interactions[1][10]. For detailed structured information, each individual factor (e.g., Factor VIII, Prothrombin) should be considered as distinct targets rather than using the umbrella term “blood coagulation proteins.”

Other names

Coagulation factorClotting factorBlood clotting factorCoagulation cascade protein

Inhibition of active coagulation enzymes (e.g., direct inhibition of thrombin [FIIa], factor Xa); Replacement therapy (providing deficient clotting factor protein); Antagonism of vitamin K-dependent factor synthesis